Journal article
Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban.
Abstract
The new oral anticoagulants dabigatran etexilate (Pradaxa), rivaroxaban (Xarelto), and apixaban (Eliquis) have predictable pharmacokinetic and pharmacodynamic profiles and are alternatives to warfarin. However, many physicians are wary of these drugs, since there is limited evidence on how to manage bleeding in patients taking them, and since no specific antidote is known to reverse their anticoagulant effect. Management requires careful …
Authors
Fawole A; Daw HA; Crowther MA
Journal
Cleveland Clinic Journal of Medicine, Vol. 80, No. 7, pp. 443–451
Publisher
Cleveland Clinic Journal of Medicine
Publication Date
July 2013
DOI
10.3949/ccjm.80a.13025
ISSN
0891-1150